Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment

Delcath Systems (DCTH) will be featured on Health Uncensored with Dr. Drew, scheduled to air nationally on November 15, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

“Precision Oncology: Changing the Game for Metastatic Liver Cancer” to air Sunday, November 15 at 5:30 p.m. ET / 2:30 pm PT on Fox Business

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday, November 15, 2026. A podcast is also expected to be released following the television broadcast.

How to Watch

• Program: Health Uncensored with Dr. Drew
• Episode title: Mario & Courtney Lopez: Health From the Inside Out
• Network: FOX Business Network
• Air date: Sunday, November 15, 2026
• Time: 5:30 p.m. ET / 2:30 pm PT

Episodes of Health Uncensored with Dr. Drew are also available following broadcast on HealthUncensoredTV.com and the show’s YouTube channel.

The program includes a discussion of percutaneous hepatic perfusion (PHP), a liver-directed approach that delivers high-dose chemotherapy directly to the liver while filtering the blood before it is returned to systemic circulation, limiting systemic exposure. Delcath’s Hepatic Delivery System is designed for use in this procedure. The program takes viewers inside a treatment center.

Gerard Michel, Chief Executive Officer of Delcath Systems, Inc. and Dr. Sachin Modi, Consultant Interventional Radiologist at University Hospital Southampton in the United Kingdom are both featured in the segment. Utilizing Delcath’s Hepatic Delivery System, University Hospital Southampton has performed more than 500 PHP procedures.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO KIT^™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) in the United States and CHEMOSAT^® Hepatic Delivery System for Melphalan in Europe, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure during a percutaneous hepatic perfusion procedure.

HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

For more information about Delcath Systems, Inc., visit the Company’s website.

Important Safety Information

HEPZATO KIT carries a boxed warning for severe peri-procedural complications and myelosuppression and is available only through a restricted program under the HEPZATO KIT REMS. Severe peri-procedural complications, including hemorrhage, hepatocellular injury and thromboembolic events, may occur. Myelosuppression can result in severe infection, bleeding or symptomatic anemia.

Please see the full Prescribing Information, including Boxed Warning, for HEPZATO KIT.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261111448568/en/

Investor Relations
ICR Healthcare
investorrelations@delcath.com

Source: Delcath Systems, Inc.

Key Terms

percutaneous hepatic perfusion medical

Percutaneous hepatic perfusion is a medical procedure that delivers high doses of cancer-fighting medicine directly to the liver through a small tube inserted into a blood vessel. It matters because it targets liver tumors more precisely, often with fewer side effects, helping to control cancer that has spread to the liver.

boxed warning regulatory

A boxed warning is the strongest safety alert a drug regulator places on a medication’s official label to highlight life‑threatening or very serious risks, similar to a bold red flag attached to a product. For investors, it matters because this warning can reduce sales, increase regulatory scrutiny, raise liability and monitoring costs, and change market perception of the drug’s future revenue and risk profile.

rems regulatory

Risk Evaluation and Mitigation Strategies (REMS) are safety programs required by regulators for certain medications to make sure their benefits outweigh known dangers; they can include extra training, special certifications for prescribers, restricted distribution channels, patient monitoring, or paperwork. For investors, REMS act like a safety checkpoint that can slow or limit a drug’s sales, raise costs, complicate manufacturing and distribution, and affect revenue forecasts and legal risk, so they matter for a product’s market potential and timeline.

myelosuppression medical

A condition where the bone marrow slows or stops making blood cells, causing low white cells (higher infection risk), red cells (fatigue, oxygen problems), or platelets (bleeding risk). Think of the marrow as a factory that supplies vital workers; when it falters, patients become vulnerable. For investors, myelosuppression matters because it can limit a drug’s safety, change dosing or monitoring needs, affect regulatory approval and label warnings, and influence commercial potential and costs.

thromboembolic events medical

Thromboembolic events are serious medical incidents where a blood clot forms and travels through the bloodstream to block a vessel, like a clot causing a stroke or a lung embolism; think of it as a sudden pipe blockage inside the body. For investors, these events matter because they can signal safety risks for drugs or devices, trigger regulatory action, costly recalls or lawsuits, and materially affect a company’s sales, valuation and future approvals.